Citations

Clear

861 citation(s) found for "Sd, Wexner".

Biologically optimized schedule of gemcitabine and nab-paclitaxel regimen in metastatic pancreatic adenocarcinoma.
Abushahin, Laith , Jin, Ning , Elkhatib, Rifat T. , Roychowdhury, Sameek , Noonan, Anne M. , Hays, John L. , Malalur, Pannaga G. , Manne, Ashish , Mittra, Arjun , Williams, Terence M.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: TPS4168-TPS4168

10.1200/jco.2021.39.15_suppl.tps4168 Get It

TPS4168 Background: Metastatic pancreatic adenocarcinoma has a poor prognosis, and improvements in therapy have been challenging. Alongside efforts in developing novel agents, there is a need to optimize and maximize the benefit of currently approved drugs. Gemcitabine + nab-paclitaxel is a frequently used regimen for pancreatic adenocarcinoma. Nab-paclitaxel is albumin–bound chemotherapy; hence the role of albumin uptake is critical for its effect. Caveolae are small membrane invaginations essential for transendothelial albumin uptake. Cav-1 is the principal structural component of caveolae. Williams and colleagues have published a series of preclinical studies demonstrating that tumor cell-specific Cav-1 expression directly correlates with albumin and albumin-bound chemotherapy uptake and subsequent apoptotic response in tumor cells. In vitro studies showed that exposure of pancreatic cancer cells to Gemcitabine resulted in up-regulation of Cav-1 peaking 48 hours after gemcitabine exposure. This Cav-1 up-regulation correlated with increased temporal albumin cellular uptake. In addition, Williams and colleagues noted that exposure of pancreatic cancer cell lines to Gemcitabine resulted in a time–specific re-entry of cells into the G2/M phase (nab-paclitaxel cytotoxicity phase) between 48-60 hours after gemcitabine treatment. Collectively this data suggest that infusing nab-paclitaxel after 48 hours of gemcitabine infusion would be optimal for both increased uptake as well as increased susceptible tumor cells. We had previously shown this effect on multiple cell lines as well as mouse models. Methods: This is a phase II trial; patients will receive a standard of care chemotherapy regimen consisting of FDA-approved Gemcitabine + nab-paclitaxel with modification of the schedule to deliver nab-paclitaxel 48 hours (2 days) after gemcitabine infusions. The primary endpoint is ORR, with a null hypothesis of 20% vs. a target of 35%. Employing a 2-stage design (minimax) and assuming 80% power and a 0.05 significance level, a total of 53 patients will be required. In the first stage, if at least 7/31 patients respond to therapy, an additional 22 patients will be added for a total of 53 patients. The study will be terminated early if ≤ six patients respond in the first stage. Observation of response in at least 16/53 patients would be required to warrant further investigation of this infusion schedule of combination therapy. The secondary endpoints include the safety of the regimen schedule, Relative dose intensity, disease control rate, PFS, and OS. The trial opened to enrollment in June 2020 and is accepting patients. Clinical trial information: NCT04115163.
Comparative diagnostic accuracy of EUS needles in solid pancreatic masses: a network meta-analysis
Han, Samuel , Bhullar, Furqan A. , Alaber, Omar , Kamal, Ayesha , Hopson, Puanani , Kanthasamy, Kavin, Coughlin, Sarah , Moreau, Christopher, Jin, David X. , Valverde‐López, Francisco , Yazıcı, Cemal , Lee, Peter J. , (CAPER), on behalf of the Collaborative Alliance for Pancreatic Education and Research, Archibugi, Livia , Thiruvengadam, Nikhil Ravi , Paragomi, Pedram , Nagpal, Sajan Jiv Singh , Papachristou, Georgios I. , Akshintala, Venkata S. , (CAPER), on behalf of the Collaborative Alliance for Pancreatic Education and Research

Mayo Clinic

Endoscopy International Open | May 27, 2021 | Volume: 09 | Issue: 06 | Pages: E853-E862

10.1055/a-1381-7301 | PMID 34079867 Get It

AbstractBackground and study aims Endoscopic ultrasound (EUS)-guided tissue sampling is the standard of care for diagnosing solid pancreatic lesions. While many two-way comparisons between needle types have been made in randomized controlled trials (RCTs), it is unclear which size and type of needle offers the best probability of diagnosis. We therefore performed a network meta-analysis (NMA) to compare different sized and shaped needles to rank the diagnostic performance of each needle.Methods We searched MEDLINE, EMBASE and Cochrane Library databases through August, 2020 for RCTs that compared the diagnostic accuracy of EUS fine-needle aspiration (FNA) and biopsy (FNB) needles in solid pancreatic masses. Using a random-effects NMA under the frequentist framework, RCTs were analyzed to identify the best needle type and sampling technique. Performance scores (P-scores) were used to rank the different needles based on pooled diagnostic accuracy. The NMA model was used to calculate pairwise relative risk (RR) with 95 % confidence intervals.Results Review of 2577 studies yielded 29 RCTs for quantitative synthesis, comparing 13 different needle types. All 22G FNB needles had an RR > 1 compared to the reference 22G FNA (Cook) needle. The highest P-scores were seen with the 22G Medtronic FNB needle (0.9279), followed by the 22G Olympus FNB needle (0.8962) and the 22G Boston Scientific FNB needle (0.8739). Diagnostic accuracy was not significantly different between needles with or without suction.Conclusions In comparison to FNA needles, FNB needles offer the highest diagnostic performance in sampling pancreatic masses, particularly with 22G FNB needles.
Superior Capsular Reconstruction: A Salvage Option for Massive Irreparable Rotator Cuff Tears with Pseudoparalysis or Subscapularis Insufficiency
Ulrich, Marisa N. , Frantz, Travis L. , Jones, Grant L. , Bishop, Julie Y. , Cvetanovich, Gregory L. , Barlow, Jonathan D. , Everhart, Joshua Scott

Mayo Clinic

Arthroscopy | May 27, 2021 | Volume: 38 | Issue: 2 | Pages: 253-261

10.1016/j.arthro.2021.05.018 | PMID 34052375 Get It

Purpose We sought to examine superior capsular reconstruction (SCR) outcomes after minimum 2‐year follow‐up and determine risk factors that were predictive of outcomes. Methods Forty consecutive patients (mean age 57.3 years, 87.5% male) who underwent SCR for massive irreparable rotator cuff tears (RCT) met the inclusion criteria. Minimum 2‐year follow‐up was obtained for 32 patients (80% follow‐up). Patient demographics and preoperative clinical findings were collected. Postoperative data, including complications, patient satisfaction, strength and range‐of‐motion (ROM), and patient‐reported outcomes were collected. Results The Hamada score was ≤2 in 88% with average acromiohumeral interval distance of 6.8 mm. Preoperatively, 6 patients had external rotation lag (19%) and 6 had pseudoparalysis (19%). Intraoperative assessment of the subscapularis demonstrated true insufficiency in 38%. There was significant improvement in forward elevation (FE) (31° increase; P = .007) and strength in all planes (all P < .05). Patient‐reported outcomes significantly improved (American Shoulder and Elbow Surgeon [ASES] 34‐point increase; visual analog scale [VAS] 2.9‐point decrease; single alpha‐numeric evaluation [SANE] 48‐point increase; all P < .05). Twenty‐six patients (81%) were completely or somewhat satisfied with surgery. At time of final follow‐up, 3/32 patients (9%) failed SCR and converted to reverse total shoulder arthroplasty. There were 4 (13%) reported complications (2 patients had postoperative falls; 1 patient had persistent severe pain; 1 had persistent stiffness). One patient was deceased. Patients with pseudoparalysis ( n = 6) had significant improvement in post‐operative FE (28 vs 154°; P < .0001) and SANE score ( P = .016) with 66% patient satisfaction. However, outcome scores overall remained lower than SCR without pseudoparalysis. Regarding subscapularis insufficiency ( n = 12), significant improvement was seen in postoperative FE (108 vs 158°; P = .019) and patient‐reported outcome scores ( P < .005). In patients converted from SCR to reverse total shoulder arthroplasty ( n = 3), there were no distinguishing characteristics present. Conclusion Superior capsular reconstruction is an effective salvage operation for massive irreparable RCT. Patients with pseudoparalysis or subscapularis insufficiency demonstrate significant postoperative improvement in FE and patient‐reported outcomes. Level of Evidence IV, retrospective cohort.
Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure
Kar, Saibal , Mack, Michael J. , Lindenfeld, JoAnn, Abraham, William T. , Asch, Federico M. , Weissman, Neil J., Enriquez‐Sarano, Maurice , Lim, D. Scott , Mishell, Jacob M. , Rogers, Jason H. , Cohen, David J., Grayburn, Paul , Stone, Gregg W. , Kar, Saibal , Enriquez-Sarano, Maurice , Lim, D Scott , Whisenant, Brian K. , Arnold, Suzanne V. , Cohen, David J.

Mayo Clinic

Circulation | May 27, 2021 | Volume: 144 | Issue: 6 | Pages: 426-437

10.1161/circulationaha.120.053061 | PMID 34039025 Get It

Background: In the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation), among 614 patients with heart failure with 3+ or 4+ secondary mitral regurgitation (MR), transcatheter mitral valve repair (TMVr) with the MitraClip reduced MR, heart failure hospitalizations, and mortality and improved quality of life compared with guideline-directed medical therapy (GDMT) alone. We aimed to examine the prognostic relationship between MR reduction and outcomes after TMVr and GDMT alone. Methods: Outcomes in COAPT between 30 days and 2 years were examined on the basis of the severity of residual MR at 30 days. Results: TMVr-treated patients had less severe residual MR at 30 days than GDMT-treated patients (0/1+, 2+, and 3+/4+: 72.9%, 19.9%, and 7.2% versus 8.2%, 26.1%, and 65.8%, respectively [ P <0.0001]). The rate of composite death or heart failure hospitalizations between 30 days and 2 years was lower in patients with 30-day residual MR of 0/1+ and 2+ compared with patients with 30-day residual MR of 3+/4+ (37.7% versus 49.5% versus 72.2%, respectively [ P <0.0001]). This relationship was consistent in the TMVr and GDMT arms ( P interaction =0.92). The improvement in Kansas City Cardiomyopathy Questionnaire score from baseline to 30 days was maintained between 30 days and 2 years in patients with 30-day MR ≤2+ but deteriorated in those with 30-day MR 3+/4+ (–0.3±1.7 versus –9.4±4.6 [ P =0.0008]) consistently in both groups ( P interaction =0.95). Conclusions: In the COAPT trial, reduced MR at 30 days was associated with greater freedom from death or heart failure hospitalizations and improved quality of life through 2-year follow-up whether the MR reduction was achieved by TMVr or GDMT. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01626079.
Accuracy of Wearable Sensor Technology in Hand Goniometry: A Systematic Review
Ávila, Francisco R. , Carter, Rickey E. , Giardi, Davide , Guliyeva, Günel , Forte, Antonio J. , Bruce, Charles J. , Giardi, Davide , Forte, Antonio Jorge , Carter, Rickey E , Avila, Francisco R , McLeod, Christopher J.

Mayo Clinic

HAND | May 25, 2021 | Volume: 18 | Issue: 2 | Pages: 340-348

10.1177/15589447211014606 | PMID 34032154 Get It

Background Wearable devices and sensor technology provide objective, unbiased range of motion measurements that help health care professionals overcome the hindrances of protractor-based goniometry. This review aims to analyze the accuracy of existing wearable sensor technologies for hand range of motion measurement and identify the most accurate one. Methods We performed a systematic review by searching PubMed, CINAHL, and Embase for studies evaluating wearable sensor technology in hand range of motion assessment. Keywords used for the inquiry were related to wearable devices and hand goniometry. Results Of the 71 studies, 11 met the inclusion criteria. Ten studies evaluated gloves and 1 evaluated a wristband. The most common types of sensors used were bend sensors, followed by inertial sensors, Hall effect sensors, and magnetometers. Most studies compared wearable devices with manual goniometry, achieving optimal accuracy. Although most of the devices reached adequate levels of measurement error, accuracy evaluation in the reviewed studies might be subject to bias owing to the use of poorly reliable measurement techniques for comparison of the devices. Conclusion Gloves using inertial sensors were the most accurate. Future studies should use different comparison techniques, such as infrared camera–based goniometry or virtual motion tracking, to evaluate the performance of wearable devices.
Abstract 15562: Incidence and Risk Factors of Device-related Infection in De Novo Transvenous Implantable Cardiac Defibrillator Medicare Patients
Jacobsen, Caroline M., Wold, Nicholas , Amorosi, Stacey L., Stivland, Timothy M. , Mark, George E., Lambiase, Pier D. , Miller, Marc A. , Lambiase, Pier D , El‐Chami, Mikhael F. , Griffiths, Robert I, Hansen, Linda K. , Knight, Bradley P. , Weiss, Raul , Biffi, Mauro , Probst, Vincent , Baddour, Larry M.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.15562 Get It

Introduction: Practice guidelines recommend use of subcutaneous implantable cardioverter-defibrillators (ICD) in patients (pts) at risk of sudden cardiac death and high risk for infection. This has prompted a need to better identify pts at high risk of infection to assist in de novo device selection. The objective of this study is to estimate infection incidence in de novo transvenous (TV) ICD implants and assess risk factors associated with infection in a large Medicare population. Methods: A retrospective cohort study was conducted using 100% Medicare administrative and claims data to identify pts who underwent de novo TV-ICD implantation between 7/2016 and 1/2018. Device-related infection within 2 years of implantation was identified using ICD-10 diagnosis and procedure codes. Baseline pt factors associated with infection were identified by univariable logistic regression analysis of all variables of interest, including factors in Charlson and Elixhauser comorbidity indices, followed by stepwise selection criteria with a p≤0.25 for inclusion in a multivariable model and a backwards, stepwise elimination process with p≤0.1 to remain in the model. A time-to-event analysis was also conducted. Results: Among 26,742 pts with de novo TV-ICD, 519 (1.9%) had a device-related infection over 2 years. The mean pt age with and without infection was 68 and 71 years, respectively. While more than half (54%) of infections occurred within 90 days post implant, infections continued to be diagnosed with 16% of infections occurring between years 1 and 2. Multivariable analysis revealed several significant predictors of infection (Figure) including age <70 years, end stage renal disease with chronic dialysis and diabetes with complications. Conclusion: The rate of de novo TV-ICD infection in a large real-world Medicare population is clinically significant. The factors associated with increased infection risk identified here can be used to help determine device selection.
Assessing food insecurity among hospitalized patients at an NCI-designated comprehensive cancer center
Husain, Marium , Hinton, Alice , Boateng, E , Leonard, Nicole, Hashi, Naima , Addissie, Selamawit, Mohamed, Mubarak , Paskett, Electra D. , Gray, Darrell M.

Mayo Clinic

No container title available | April 28, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-340289/v1 Get It

Abstract PURPOSE: To evaluate the prevalence of food insecurity among patients with cancer and to validate the Hunger Vital Sign (HVS) instrument compared to the standard-of-care USDA 18-item Household Food Security Scale (HFSS). The secondary objective was to assess disparities in food access based on race, zip code and insurance status.PATIENTS AND METHODS: Patients with cancer who were hospitalized at The Ohio State University James Comprehensive Cancer Center (OSU-CCC) were identified to participate by the Department of Social Work. Each patient completed the HVS and the 18-item HFSS. The prevalence of food insecurity was estimated and 95% Wilson score confidence intervals were calculated. The agreement between the prevalence of food insecurity as measured by the two different instruments were compared through the use of McNemar’s test. Disparities in food access based on race, zip code and insurance status were further assessed with Fisher exact tests. RESULTS: One hundred and twelve patients participated. We found that the HVS identified food insecurity in 14.3% (95% Confidence Interval (CI): 9.1, 21.7) of participants, whereas the 18-item HFSS identified 8.6% (95% CI: 4.8, 15.1) of participants. However, there was no significant difference between food insecurity as measured by the HVS and the 18-item HFSS (p = 0.289). There were also no significant differences in food insecurity based on race, insurance status or geographical location of patients.CONCLUSION: The HVS is an alternative to the 18-item HFSS as a valid tool to assess food security amongst hospitalized patients with cancer.
High school female basketball athletes exhibit decreased knee‐specific choice visual‐motor reaction time
Schilaty, Nathan D. , Bies, Nicholas J., McPherson, April L. , Hewett, Timothy E. , Nagai, Takashi , Schilaty, Nathan D , Bates, Nathaniel A , Nagai, Takashi , Bates, Nathaniel A.

Mayo Clinic

Scandinavian Journal of Medicine & Science in Sports | April 28, 2021 | Volume: 31 | Issue: 8 | Pages: 1699-1707

10.1111/sms.13978 | PMID 33908068 Get It

Weaker hamstrings muscular forces and lower ratio of the hamstrings/quadriceps muscular forces in female athletes have been identified as modifiable risk factors for anterior cruciate ligament (ACL) injuries. However, sex differences in athletes’ ability to react to visual cues (Choice Visual‐Motor Reaction Time: VMRT) and to generate knee muscular forces (rate of force development: RFD) immediately following the visual cues were largely unknown. Therefore, the purpose of the study was to examine sex differences in Choice VMRT and RFD. A total of 50 high school basketball athletes (26F/24 M) participated in the study. Subjects sat in the knee dynamometer chair with their knee secured at 70° of knee flexion and performed knee extension or flexion maximum voluntary isometric contractions immediately after they saw the visual cue: “UP” or “DOWN” arrows, respectively. Choice VMRT was defined as the time between the visual cue and the initiation of muscular force development (>5Newtons). RFD was calculated by dividing the changes in forces over the changes in time at four time points (0–50/100/150/200 ms). Peak muscular forces and RFD were normalized to their body mass. Average of three trials in each direction (flexion and extension) in each leg was used for statistical analyses. Females had significantly slower Choice VMRT (p < 0.001–0.027) and lower knee extension RFD at 100 ms (p = 0.005). In addition, females had significantly higher knee flexion/extension ratio than males in late RFD (150 ms and 200 ms) (p < 0.004). The current study has provided additional sensorimotor characteristics of athletes and sexes in addition to their knee muscular characteristics.